vs
CORE MOLDING TECHNOLOGIES INC（CMT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是CORE MOLDING TECHNOLOGIES INC的1.7倍（$127.1M vs $74.7M），CORE MOLDING TECHNOLOGIES INC同比增速更快（19.5% vs 17.1%），CORE MOLDING TECHNOLOGIES INC自由现金流更多（$-2.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -2.2%）
科模成型技术公司1988年成立，总部位于美国俄亥俄州哥伦布市，主要生产片状模塑料以及模压玻纤增强塑料，生产总面积超100万平方英尺，在墨西哥马塔莫罗斯、美国南卡罗来纳州加夫尼、俄亥俄州辛辛那提设有主要分支机构，2011年成立了子公司科瑞特种复合材料有限公司。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CMT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.7倍
$74.7M
营收增速更快
CMT
高出2.4%
17.1%
自由现金流更多
CMT
多$23.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $74.7M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 15.2% | 51.0% |
| 营业利润率 | 4.8% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 19.5% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.35 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMTZLAB
| Q4 25 | $74.7M | $127.1M | ||
| Q3 25 | $58.4M | $115.4M | ||
| Q2 25 | $79.2M | $109.1M | ||
| Q1 25 | $61.4M | $105.7M | ||
| Q4 24 | $62.5M | $108.5M | ||
| Q3 24 | $73.0M | $101.8M | ||
| Q2 24 | $88.7M | $100.1M | ||
| Q1 24 | $78.1M | $87.1M |
净利润CMTZLAB
| Q4 25 | — | — | ||
| Q3 25 | $1.9M | $-36.0M | ||
| Q2 25 | $4.1M | $-40.7M | ||
| Q1 25 | $2.2M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.2M | $-41.7M | ||
| Q2 24 | $6.4M | $-80.3M | ||
| Q1 24 | $3.8M | $-53.5M |
毛利率CMTZLAB
| Q4 25 | 15.2% | 51.0% | ||
| Q3 25 | 17.4% | 59.5% | ||
| Q2 25 | 18.1% | 60.6% | ||
| Q1 25 | 19.2% | 63.6% | ||
| Q4 24 | 15.8% | 61.5% | ||
| Q3 24 | 16.9% | 64.1% | ||
| Q2 24 | 20.0% | 64.9% | ||
| Q1 24 | 17.0% | 61.4% |
营业利润率CMTZLAB
| Q4 25 | 4.8% | -54.6% | ||
| Q3 25 | 4.4% | -42.3% | ||
| Q2 25 | 6.6% | -50.3% | ||
| Q1 25 | 4.6% | -53.3% | ||
| Q4 24 | 1.4% | -62.6% | ||
| Q3 24 | 4.9% | -66.6% | ||
| Q2 24 | 8.4% | -76.0% | ||
| Q1 24 | 6.1% | -80.7% |
净利率CMTZLAB
| Q4 25 | — | — | ||
| Q3 25 | 3.2% | -31.2% | ||
| Q2 25 | 5.1% | -37.3% | ||
| Q1 25 | 3.6% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.3% | -40.9% | ||
| Q2 24 | 7.2% | -80.2% | ||
| Q1 24 | 4.8% | -61.4% |
每股收益（稀释后）CMTZLAB
| Q4 25 | $0.35 | $-0.05 | ||
| Q3 25 | $0.22 | $-0.03 | ||
| Q2 25 | $0.47 | $-0.04 | ||
| Q1 25 | $0.25 | $-0.04 | ||
| Q4 24 | $-0.01 | $-0.09 | ||
| Q3 24 | $0.36 | $-0.04 | ||
| Q2 24 | $0.73 | $-0.08 | ||
| Q1 24 | $0.43 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $38.1M | $689.6M |
| 总债务越低越好 | $17.6M | — |
| 股东权益账面价值 | $158.2M | $715.5M |
| 总资产 | $228.1M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.11× | — |
8季度趋势，按日历期对齐
现金及短期投资CMTZLAB
| Q4 25 | $38.1M | $689.6M | ||
| Q3 25 | $42.4M | $717.2M | ||
| Q2 25 | $43.2M | $732.2M | ||
| Q1 25 | $44.5M | $757.3M | ||
| Q4 24 | $41.8M | $779.7M | ||
| Q3 24 | $42.3M | $616.1M | ||
| Q2 24 | $37.8M | $630.0M | ||
| Q1 24 | $26.6M | $650.8M |
总债务CMTZLAB
| Q4 25 | $17.6M | — | ||
| Q3 25 | $18.2M | — | ||
| Q2 25 | $18.8M | — | ||
| Q1 25 | $19.2M | — | ||
| Q4 24 | $19.7M | — | ||
| Q3 24 | $20.2M | — | ||
| Q2 24 | $20.6M | — | ||
| Q1 24 | $21.1M | — |
股东权益CMTZLAB
| Q4 25 | $158.2M | $715.5M | ||
| Q3 25 | $155.4M | $759.9M | ||
| Q2 25 | $153.5M | $791.7M | ||
| Q1 25 | $149.9M | $810.8M | ||
| Q4 24 | $147.4M | $840.9M | ||
| Q3 24 | $147.8M | $667.7M | ||
| Q2 24 | $147.5M | $704.2M | ||
| Q1 24 | $142.8M | $762.2M |
总资产CMTZLAB
| Q4 25 | $228.1M | $1.2B | ||
| Q3 25 | $219.7M | $1.2B | ||
| Q2 25 | $219.9M | $1.2B | ||
| Q1 25 | $223.6M | $1.2B | ||
| Q4 24 | $209.6M | $1.2B | ||
| Q3 24 | $220.7M | $985.3M | ||
| Q2 24 | $225.7M | $987.4M | ||
| Q1 24 | $212.3M | $988.4M |
负债/权益比CMTZLAB
| Q4 25 | 0.11× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | -3.9% | -21.0% |
| 资本支出强度资本支出/营收 | 10.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $1.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CMTZLAB
| Q4 25 | $5.0M | $-26.0M | ||
| Q3 25 | $4.6M | $-32.0M | ||
| Q2 25 | $3.5M | $-31.0M | ||
| Q1 25 | $6.1M | $-61.7M | ||
| Q4 24 | $5.0M | $-55.8M | ||
| Q3 24 | $9.2M | $-26.8M | ||
| Q2 24 | $15.9M | $-42.2M | ||
| Q1 24 | $5.1M | $-90.1M |
自由现金流CMTZLAB
| Q4 25 | $-2.9M | $-26.7M | ||
| Q3 25 | $-346.0K | $-35.0M | ||
| Q2 25 | $880.0K | $-33.9M | ||
| Q1 25 | $4.3M | $-63.2M | ||
| Q4 24 | $509.0K | $-58.4M | ||
| Q3 24 | $7.0M | $-28.2M | ||
| Q2 24 | $13.0M | $-42.9M | ||
| Q1 24 | $3.2M | $-91.1M |
自由现金流率CMTZLAB
| Q4 25 | -3.9% | -21.0% | ||
| Q3 25 | -0.6% | -30.4% | ||
| Q2 25 | 1.1% | -31.1% | ||
| Q1 25 | 7.0% | -59.9% | ||
| Q4 24 | 0.8% | -53.8% | ||
| Q3 24 | 9.6% | -27.7% | ||
| Q2 24 | 14.6% | -42.9% | ||
| Q1 24 | 4.1% | -104.5% |
资本支出强度CMTZLAB
| Q4 25 | 10.7% | 0.5% | ||
| Q3 25 | 8.4% | 2.6% | ||
| Q2 25 | 3.3% | 2.6% | ||
| Q1 25 | 2.9% | 1.5% | ||
| Q4 24 | 7.2% | 2.4% | ||
| Q3 24 | 3.1% | 1.3% | ||
| Q2 24 | 3.3% | 0.7% | ||
| Q1 24 | 2.4% | 1.1% |
现金转化率CMTZLAB
| Q4 25 | — | — | ||
| Q3 25 | 2.44× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 2.79× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | 2.47× | — | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMT
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
